EU fines generic-drug companies to end "pay for delay" deals

06/3/2013 | Chicago Tribune (tiered subscription model)

The European Commission has announced fines against Lundbeck in Denmark, Merck in Germany and seven smaller firms for arrangements under which brand-name drug companies paid generic manufacturers to delay production of cheaper off-patent medicines. The fines mark a continuing effort by EU and US regulators to end such "pay for delay" tactics by large pharmaceutical firms. Lundbeck denied wrongdoing.

View Full Article in:

Chicago Tribune (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA